Not Yet, and Not Without the Team That Knows Her: Anti-Obesity Drugs After a Binge-Eating Relapse
A woman with a recently recurrent binge-eating disorder asks about weight-loss medication — a request that runs directly into the real risk that appetite-altering pharmacotherapy could destabilize a still-fragile remission.
Natalie F., a 33-year-old marketing coordinator, asked her primary care physician about a GLP-1 agonist at what was meant to be a routine annual physical, phrasing it almost apologetically, as though she expected to be told no before she'd finished the sentence. Her chart told a more complicated story than the question suggested: a binge-eating disorder diagnosis at 22, six years of hard-won, genuinely stable remission through structured therapy, and a recurrence eighteen months ago following a job loss and a breakup that arrived within the same month of each other.
She has been back in treatment since the recurrence, sessions increased from monthly to weekly, and describes real but incomplete progress — fewer binge episodes than at the recurrence's worst point, but not yet the sustained stretch of stability that defined her original six-year remission. Her BMI has climbed to 31 over the same period, and her question about a weight-loss medication came from a place that was at least partly about the number on the scale and at least partly, by her own admission when asked directly, about wanting some sense of control back over her eating after a year and a half of feeling like she'd lost it.
That second, unprompted admission is the detail that actually shapes today's answer more than the BMI does, since a drug that works partly by altering the relationship between hunger cues and eating behavior is not a neutral tool to hand someone whose disorder is itself organized around a loss of control over exactly that relationship.
In clinic, a question asked almost apologetically
I would not start any anti-obesity pharmacotherapy today, and I want to be direct about why: her binge-eating disorder was in full remission for six years before it recurred eighteen months ago, and initiating a drug that suppresses appetite and alters her relationship with food and eating cues, in a patient whose eating disorder is defined by a loss of control around exactly those cues, carries a real risk of destabilizing a still-fragile remission rather than simply adding a weight-management tool on top of it.
I want to raise a genuine complication to that position rather than just accept or reject it: there's actual emerging data — Grilo and colleagues' randomized work on semaglutide in binge-eating disorder, alongside several retrospective cohorts — suggesting GLP-1 receptor agonists may reduce binge-eating frequency in some patients with the disorder specifically, by blunting the loss-of-control eating episodes themselves, not just suppressing baseline appetite. That's a real, if still preliminary, counter-argument to treating appetite suppression as uniformly destabilizing for this population.
I'm not proposing we start it today — her disorder is too recently recurrent and not yet re-stabilized for that data to responsibly apply here — but I don't think 'any anti-obesity drug is categorically wrong for anyone with an eating disorder history' is quite the right lesson to take from her case either.
That's a fair distinction, and I'd draw the line specifically at re-stabilization, not at her diagnosis category as a permanent disqualifier. My recommendation for her today stands: no pharmacotherapy until her binge-eating disorder has been back in sustained remission, confirmed over real time, with her eating-disorder treatment team directly involved in any future decision to reconsider — not made unilaterally in a general medicine or endocrinology visit without them at the table.
Agreed: defer any anti-obesity pharmacotherapy, prioritize her intensified eating-disorder treatment, and establish direct communication between primary care and her eating-disorder team so that any future reconsideration of medication happens with that team at the table, not as a separate decision made without them.
No real disagreement remained about today's plan; the pharmacologist's point about emerging GLP-1/binge-eating data was treated as relevant to a possible future conversation once Natalie's remission is genuinely re-established, not as grounds to reconsider today's deferral.